Abbvie Inc (ABBV)

$262.90 -2.89 (-1.09%)
Market Cap 469.60B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 24.33
Forward PE 18.82
Profit Margin 6.91%
Debt to Equity Ratio -12.03
Volume 3,308,800
Avg Vol 6,935,440
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 79%
Beta 0.30
Analysts Strong Sell
Price Target $276.37

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 12:08 PM
$SLS $MRK $MRNA Why was $ABBV unable to enroll patients on BAT for VIALE-M? while we are seeing miraculous extended survival in the SLS p3? I’ve been here a long time if your interested in some Dd scroll my posts. Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.
0 · Reply
EthelSmith471
EthelSmith471 Aug. 27 at 7:29 AM
$ON $TWST $MARA $PDD $ABBV ON Semiconductor benefits from automotive and power-semiconductor demand, Twist Bioscience benefits from synthetic-biology and genomics demand, Marathon remains tied to Bitcoin-mining economics, PDD benefits from Chinese e-commerce activity, and AbbVie benefits from pharmaceutical demand and pipeline development. I'm watching auto-chip demand, biotech orders, Bitcoin prices, Chinese consumption, and prescription growth.
0 · Reply
focafoca99
focafoca99 Aug. 27 at 6:10 AM
$ABBV submitted an EMA application for SKYRIZI subcutaneous induction in adult Crohn's disease. https://www.rapidticker.com/news/abbv-abbvie-submits-regulatory-application-to-e4013f
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 5:12 AM
$SLS $MRK $MRNA Why was $ABBV unable to enroll patients on BAT - while we are seeing miraculous extended survival in the SLS p3? I’ve been here a long time if your interested in some Dd scroll my posts. Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 5:03 AM
$SLS While we wait for Imminent Phase 3 Results, where we are seeing miraculous survival 40% of enrolled Second Remission CR2 patients surviving nearly 3 years, in a trial where survival on BAT is stated to be just 6-8 months. important note: $ABBV conducted a Phase 3 trial combing Aza+Ven, BAT for Control patients, for First Remission CR1 maintenance. VIALE-M Aza+Ven P3 for CR1 maintenance - FAILED ABBV REPORTED AN INABILITY TO ENROLL… • Unheard of miraculous Survival in the SlS CR2 P3 and abbv ’says’ they can’t enroll their CR1 trial. Viale-T also Failed Verona Failed Opti-Aml RIT Aza+ Ven Failed $MRK $MRNA
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 8:30 PM
$SLS $MRK $MRNA $ABBV Gps Phase 2 Trial MOS in this First Remission Non-transplant setting was not reached, > 67.6 months -Vs - 19 months w BAT. Direct Head to Comparable: GPS MOS not Reached > 67.6 months vs BAT 19* really 17.3 months TT vs duration of remission, Gps measure.
0 · Reply
CapitalMonk
CapitalMonk Aug. 26 at 7:19 PM
$ABBV Price: $261.89 (-1.47%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±2.53% RSI: 72.3 | Momentum: Moderate Volume: -65.0% vs avg Volatility: 1.59% Support: $241.20 | Resistance: $266.97 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
TwongStocks
TwongStocks Aug. 26 at 5:21 PM
$APGE Equity Corporate Actions Alert #2026 - 607 Information Regarding the Merger of Apogee Therapeutics, Inc. (APGE) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-607 At a special meeting held on August 11, 2026, the shareholders of Apogee Therapeutics, Inc. (APGE), approved the proposed merger with and into AbbVie Inc. (NYSE: $ABBV ). The merger is tentatively scheduled to close prior to the market open on September 3, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 2, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (September 3rd) and will be suspended effective September 4, 2026. APGE shareholders will receive $135.11 per share at closing.
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 26 at 5:08 PM
🚨 $ABBV UPDATE 🚨 ABBV is pulling back after getting rejected around the $266 area. But here’s the important part: the company’s fundamentals remain strong. 📊 Q2 revenue: $16.99B (+10.2% YoY) 💰 Adjusted EPS: $3.65 🔥 Skyrizi: +24% 🔥 Rinvoq: +24% ⚠️ Humira: -35.9% AbbVie also raised its 2026 revenue outlook to roughly $67.6B, while slightly lowering EPS guidance because of the Apogee acquisition. For the chart, I’m watching $266–$267.47 as the key upside zone. If ABBV reclaims that area with volume, momentum could strengthen. If it keeps losing support instead, I want to see stabilization before calling a reversal. Strong company ≠ automatic bullish trade. Let price confirm. 📈
0 · Reply
Pas_wayne
Pas_wayne Aug. 26 at 4:56 PM
$ABBV 28/8 $257.5p @ $1.04 Four-day inside bar + high-confidence downside setup.
0 · Reply
Latest News on ABBV
AbbVie submits Skyrizi application to the EMA

2026-08-27T09:21:03.000Z - 3 hours ago

AbbVie submits Skyrizi application to the EMA

AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Aug 27, 2026, 2:00 AM EDT - 6 hours ago

AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Emily Field: Large pharma companies are going to continue looking at biotech

Aug 24, 2026, 10:45 AM EDT - 2 days ago

Emily Field: Large pharma companies are going to continue looking at biotech

IBB MRK MRNA XLV

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

Aug 21, 2026, 7:45 AM EDT - 6 days ago

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

AbbVie price target raised to $303 from $298 at Piper Sandler

2026-08-20T10:55:24.000Z - 7 days ago

AbbVie price target raised to $303 from $298 at Piper Sandler

AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

Aug 18, 2026, 8:00 AM EDT - 9 days ago

AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

AbbVie price target raised to $300 from $295 at Wells Fargo

2026-08-17T10:55:57.000Z - 10 days ago

AbbVie price target raised to $300 from $295 at Wells Fargo

AbbVie upgraded to Outperform from Peer Perform at Wolfe Research

2026-08-17T08:29:38.000Z - 10 days ago

AbbVie upgraded to Outperform from Peer Perform at Wolfe Research

Expert explains why healthcare is a top-performing sector

Aug 13, 2026, 11:15 PM EDT - 13 days ago

Expert explains why healthcare is a top-performing sector

AMGN BIIB GILD JNJ LLY MRK UNH

AbbVie price target raised to $260 from $246 at Evercore ISI

2026-08-10T12:16:02.000Z - 17 days ago

AbbVie price target raised to $260 from $246 at Evercore ISI

AbbVie upgraded to Buy from Hold at Erste Group

2026-08-05T14:36:14.000Z - 21 days ago

AbbVie upgraded to Buy from Hold at Erste Group

AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA

2026-08-04T13:35:25.000Z - 22 days ago

AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA

AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic

2026-08-04T12:10:59.000Z - 23 days ago

AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

Aug 4, 2026, 8:00 AM EDT - 23 days ago

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

AbbVie price target raised to $288 from $261 at Guggenheim

2026-08-04T10:52:04.000Z - 23 days ago

AbbVie price target raised to $288 from $261 at Guggenheim

AbbVie price target raised to $285 from $265 at Cantor Fitzgerald

2026-08-03T12:42:03.000Z - 24 days ago

AbbVie price target raised to $285 from $265 at Cantor Fitzgerald

AbbVie price target raised to $296 from $278 at Morgan Stanley

2026-08-03T12:06:31.000Z - 24 days ago

AbbVie price target raised to $296 from $278 at Morgan Stanley

AbbVie price target raised to $290 from $282 at Canaccord

2026-08-03T11:06:04.000Z - 24 days ago

AbbVie price target raised to $290 from $282 at Canaccord

AbbVie says ‘quite pleased’ with Skyrizi momentum

2026-07-31T14:01:14.000Z - 26 days ago

AbbVie says ‘quite pleased’ with Skyrizi momentum

AbbVie raises FY26 revenue view to about $67.6B from about $67.3B

2026-07-31T13:31:24.000Z - 26 days ago

AbbVie raises FY26 revenue view to about $67.6B from about $67.3B

AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84

2026-07-31T13:30:48.000Z - 26 days ago

AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84

AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 26 days ago

AbbVie Earnings Call Transcript: Q2 2026

AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 26 days ago

AbbVie Earnings release: Q2 2026

AbbVie Quarterly report: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 26 days ago

AbbVie Quarterly report: Q2 2026

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

Jul 31, 2026, 8:36 AM EDT - 27 days ago

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

Jul 31, 2026, 8:31 AM EDT - 27 days ago

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

Jul 31, 2026, 7:50 AM EDT - 27 days ago

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 27 days ago

AbbVie Reports Second-Quarter 2026 Financial Results

JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 4 weeks ago

JUVÉDERM® Day Returns to U.S. on August 19

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jul 29, 2026, 3:00 AM EDT - 4 weeks ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

Jul 29, 2026, 3:00 AM EDT - 4 weeks ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jul 23, 2026, 4:00 PM EDT - 4 weeks ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

GMAB

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jul 17, 2026, 8:00 AM EDT - 5 weeks ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Jul 14, 2026, 8:05 AM EDT - 6 weeks ago

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Jul 13, 2026, 5:06 PM EDT - 6 weeks ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

APGE SBIO

Buy these quality, low-stress stocks for the summer, says Jefferies

Jul 7, 2026, 11:45 AM EDT - 7 weeks ago

Buy these quality, low-stress stocks for the summer, says Jefferies

AXP HD LOW MCD NFLX PEP PG

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Jul 6, 2026, 1:45 PM EDT - 7 weeks ago

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 2 months ago

US House committee opens investigation into Merck, AbbVie China drug trials

MRK

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 29, 2026, 4:15 PM EDT - 2 months ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:10 AM EDT - 2 months ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Jun 29, 2026, 3:00 AM EDT - 2 months ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 4:50 PM EDT - 2 months ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 2 months ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 2 months ago

AbbVie's $11 Billion Immunology Bet

APGE

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 24, 2026, 8:00 AM EDT - 2 months ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 8:00 AM EDT - 2 months ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 5:00 AM EDT - 2 months ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 23, 2026, 3:00 AM EDT - 2 months ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

EC

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 2 months ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Press release: M&A announcement

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 2 months ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 2 months ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 2 months ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 2 months ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

Jun 19, 2026, 11:17 AM EDT - 2 months ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 2 months ago

AbbVie Declares Quarterly Dividend

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 16, 2026, 8:00 AM EDT - 2 months ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 12, 2026, 3:00 AM EDT - 2 months ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 10, 2026, 11:47 AM EDT - 2 months ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:40 AM EDT - 2 months ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 8, 2026, 8:00 AM EDT - 2 months ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 7:04 PM EDT - 3 months ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 3 months ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 8:00 AM EDT - 3 months ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 29, 2026, 8:00 AM EDT - 3 months ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 12:08 PM
$SLS $MRK $MRNA Why was $ABBV unable to enroll patients on BAT for VIALE-M? while we are seeing miraculous extended survival in the SLS p3? I’ve been here a long time if your interested in some Dd scroll my posts. Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.
0 · Reply
EthelSmith471
EthelSmith471 Aug. 27 at 7:29 AM
$ON $TWST $MARA $PDD $ABBV ON Semiconductor benefits from automotive and power-semiconductor demand, Twist Bioscience benefits from synthetic-biology and genomics demand, Marathon remains tied to Bitcoin-mining economics, PDD benefits from Chinese e-commerce activity, and AbbVie benefits from pharmaceutical demand and pipeline development. I'm watching auto-chip demand, biotech orders, Bitcoin prices, Chinese consumption, and prescription growth.
0 · Reply
focafoca99
focafoca99 Aug. 27 at 6:10 AM
$ABBV submitted an EMA application for SKYRIZI subcutaneous induction in adult Crohn's disease. https://www.rapidticker.com/news/abbv-abbvie-submits-regulatory-application-to-e4013f
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 5:12 AM
$SLS $MRK $MRNA Why was $ABBV unable to enroll patients on BAT - while we are seeing miraculous extended survival in the SLS p3? I’ve been here a long time if your interested in some Dd scroll my posts. Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 5:03 AM
$SLS While we wait for Imminent Phase 3 Results, where we are seeing miraculous survival 40% of enrolled Second Remission CR2 patients surviving nearly 3 years, in a trial where survival on BAT is stated to be just 6-8 months. important note: $ABBV conducted a Phase 3 trial combing Aza+Ven, BAT for Control patients, for First Remission CR1 maintenance. VIALE-M Aza+Ven P3 for CR1 maintenance - FAILED ABBV REPORTED AN INABILITY TO ENROLL… • Unheard of miraculous Survival in the SlS CR2 P3 and abbv ’says’ they can’t enroll their CR1 trial. Viale-T also Failed Verona Failed Opti-Aml RIT Aza+ Ven Failed $MRK $MRNA
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 8:30 PM
$SLS $MRK $MRNA $ABBV Gps Phase 2 Trial MOS in this First Remission Non-transplant setting was not reached, > 67.6 months -Vs - 19 months w BAT. Direct Head to Comparable: GPS MOS not Reached > 67.6 months vs BAT 19* really 17.3 months TT vs duration of remission, Gps measure.
0 · Reply
CapitalMonk
CapitalMonk Aug. 26 at 7:19 PM
$ABBV Price: $261.89 (-1.47%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±2.53% RSI: 72.3 | Momentum: Moderate Volume: -65.0% vs avg Volatility: 1.59% Support: $241.20 | Resistance: $266.97 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
TwongStocks
TwongStocks Aug. 26 at 5:21 PM
$APGE Equity Corporate Actions Alert #2026 - 607 Information Regarding the Merger of Apogee Therapeutics, Inc. (APGE) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-607 At a special meeting held on August 11, 2026, the shareholders of Apogee Therapeutics, Inc. (APGE), approved the proposed merger with and into AbbVie Inc. (NYSE: $ABBV ). The merger is tentatively scheduled to close prior to the market open on September 3, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 2, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (September 3rd) and will be suspended effective September 4, 2026. APGE shareholders will receive $135.11 per share at closing.
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 26 at 5:08 PM
🚨 $ABBV UPDATE 🚨 ABBV is pulling back after getting rejected around the $266 area. But here’s the important part: the company’s fundamentals remain strong. 📊 Q2 revenue: $16.99B (+10.2% YoY) 💰 Adjusted EPS: $3.65 🔥 Skyrizi: +24% 🔥 Rinvoq: +24% ⚠️ Humira: -35.9% AbbVie also raised its 2026 revenue outlook to roughly $67.6B, while slightly lowering EPS guidance because of the Apogee acquisition. For the chart, I’m watching $266–$267.47 as the key upside zone. If ABBV reclaims that area with volume, momentum could strengthen. If it keeps losing support instead, I want to see stabilization before calling a reversal. Strong company ≠ automatic bullish trade. Let price confirm. 📈
0 · Reply
Pas_wayne
Pas_wayne Aug. 26 at 4:56 PM
$ABBV 28/8 $257.5p @ $1.04 Four-day inside bar + high-confidence downside setup.
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 26 at 4:54 PM
$ABBV 28 AUG 26 $257.5 PUT $1.04
0 · Reply
Snipertradesexpert
Snipertradesexpert Aug. 26 at 4:54 PM
$ABBV 28 AUG 26 $257.5 PUT $1.04
0 · Reply
Alphatrades09
Alphatrades09 Aug. 26 at 4:54 PM
$ABBV 257.5P 8/28 @ 1.04 🦅
0 · Reply
ZacksResearch
ZacksResearch Aug. 26 at 4:32 PM
$LLY vs. $ABBV — which stock has the stronger growth story? 🔥 Lilly’s 2026 sales and EPS estimates imply 35.4% and 48.4% year-over-year growth, respectively, while AbbVie’s imply 10.5% and 40.6%. 🚀 Lilly: $27.6B from Mounjaro + Zepbound in the first half of 2026 📈 AbbVie: Skyrizi + Rinvoq expected to exceed $31B in 2026 💡 Lilly’s stronger growth trajectory and expanding obesity opportunity make it the better pick. Latest LLY news here 👉 https://www.zacks.com/stock/quote/LLY?cid=sm-stocktwits-0-quote_overview-oc-39386&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39386
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 3:38 PM
$SLS $MRK $MRNA Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.
0 · Reply
Tom2772
Tom2772 Aug. 26 at 2:57 PM
$REGN $ABBV $RHHBY Interesting LYTENAVA Interview This interview is already about a week old, but it’s still very interesting and worth highlighting. A sponsored, retina-focused interview for the U.S. LYTENAVA rollout, aimed less at investors and more at raising awareness within the medical community — especially among retina specialists — ahead of the U.S. launch. Bob Jahr, CEO of Outlook Therapeutics, discusses the FDA approval, LYTENAVA, and its path into retina practice. Dr. Barry Kuppermann, MD, PhD, moderates the interview. He is a practicing retina specialist, Professor and Chair of Ophthalmology & Visual Sciences, as well as Director of the Gavin Herbert Eye Institute at UC Irvine. This puts LYTENAVA directly in front of the medical audience that matters for the U.S. launch. Interesting.. very interesting.. 👀 https://eyetube.net/podcasts/new-retina-radio/the-story-behind-lytenava-from-fda-approval-to-retina-practice
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 5:31 AM
$SLS $ABBV Is any day now a long time to wait for a 10X to 20X Return on an Investment? We are at the finish Line -and at 5 year High Share Price Waiting for the IMMINENTLY DUE PH3 Results. • 106 Days Since the 78th Event -- while we await 80th -- in a trial where we have truly miraculous survival - for 49 Second Remission CR2 Patients, who are too frail, for transplant. • 60th EVENT Dec 10, 2024 - IDMC UNBLINDED ACTUAL MOS and IR DATA - share price jumped 60% including an offering that doubled the share count - SLS MCAP tripled that week. • 72nd EVENT Dec 26th 2025 - 12 Events in 12 months - its now been 106 - the Share Price Doubled • 78th EVENT May 11, 2206 - 6 Events in 4.5 Months - its now been 106 - the Share Price CRANKED -- Nearly Tripling ... The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA from the INTERIM ANALYSIS that told all the AML players... Gps is Golden - just like ALL Prior Gps trials. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 4:45 AM
$SLS $ABBV Positive P3 result is coming, any day now, and it'll give Gps the fda greenlight to treat 50,000 Aml remission patients each year and generate $20B a year in real revenue. That is worth a f ton more than the current short rigged $2.89B market cap. Is any Day Now a long time to wait for a 10X to 20X Return on an Investment?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 2:20 AM
$SLS $MRK SLS is the Next$MRNA P3 Results Imminent The Gps +Keytruda Phase 2 Combination Trial Data - GPS WT1 Targeted Cancer Vaccine - now in nearly Complete Phase 3 Trial for AML Remission Maintenance is the Closest thing there is to the MRNA Keytruda Trial. Gps has proven Effective in preventing Relapse and Extending Survival 2x 4x in all Prior Trials • Including 2 Phase 2's for AML Remission Maintenance, the Phase 3 Trial Setting. 128 Patients Randomized to BAT - Best Available Treatment or Gps Immunotherapy. Aza+VEN is the BAT for Control ARM Patients, and it Recently Failed 3 Phase 3 Trials conducted by $ABBV - Including Failing the VIALE-M P3 for AML First Remission Maintenance and Failing the VIALE-T Post Transplant Maintenance Trial.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 2:04 AM
$SLS Gps Phase 1/2 Combination Results w Keytruda $MRK - MOS of 18.4 months for End Stage Refractory, Platinum Resistant Ovarian Cancer Patients. • MOS 18.4 Months / Longer than $IMGN Elahere 16.4 month MOS in the same Exact Setting (- except 50% were refractory / 75% in Gps P2). $ABBV Paid $10B to buy Elahere $IMGN - and GPS PH2 trial results are better. ... https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won $SLS is the Next $MRNA ---
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 12:00 AM
$SLS $ABBV $SLS $ABBV $MRNA Is any day now a long time to wait for a 10X to 20X Return on an Investment? We are at the finish Line -and at 5 year High Share Price Waiting for the IMMINENTLY DUE PH3 Results. • 106 Days Since the 78th Event -- while we await 80th -- in a trial where we have truly miraculous survival - for 49 Second Remission CR2 Patients, who are too frail, for transplant. • 60th EVENT Dec 10, 2024 - IDMC UNBLINDED ACTUAL MOS and IR DATA - share price jumped 60% including an offering that doubled the share count - SLS MCAP tripled that week. • 72nd EVENT Dec 26th 2025 - 12 Events in 12 months - its now been 106 - the Share Price Doubled • 78th EVENT May 11, 2206 - 6 Events in 4.5 Months - its now been 106 - the Share Price CRANKED -- Nearly Tripling ... The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA from the INTERIM ANALYSIS that told all the AML players... Gps is Golden - just like all the Prior trials. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 9:36 PM
$SLS 28 Weeks of Survival w BAT vs 28 Months of Survival for GPs Immune Responders ... in end stage Mesothelioma. -- Immune response is correlated with Extended Survival in all GPs Trials - IDMC UNBLINDED P3 Interim Data: Gps Elicted Immune Response in 80% of Tested Patients.... Gps has proven effective preventing relapse and extending survival in all 7 prior Trials. - Including 2 Phase 2 Trials for AML remission maintenance ... and while we are seeing Miraculous Survival in this Imminently Finished P3... -- Aza+VEN the BAT for Control Arm Patients - Recently FAILED 3 Large Phase 3 Trials Conducted by $ABBV - including Failing 2 P3's for AML Maintenance - VIALE-M and VIALE-T FAILED. - 10 15x Bagger ANY DAY NOW
0 · Reply